Completed PHASE2 INTERVENTIONAL NCT00039429

Atrasentan in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer

A Phase II Trial Evaluating Atrasentan In Patients With Advanced Renal Cell Carcinoma

Sponsor: Eastern Cooperative Oncology Group

Updated 8 times since 2017 Last updated: Jun 21, 2023 Started: Jul 14, 2003 Primary completion: Apr 30, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Kidney Cancer and is currently completed. Eastern Cooperative Oncology Group leads this study, which shows 8 recorded versions since 2003 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jul 2023 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2023 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jul 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Data source: Eastern Cooperative Oncology Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adrian, United States , Aiken, United States , Akron, United States , Ames, United States , Ann Arbor, United States , Athens, United States , Augusta, United States , Aurora, United States , Baltimore, United States , Baton Rouge, United States and 107 more locations